Nasopharyngeal cancer

A persistent neck lump, blood-stained nasal discharge, one-sided ear blockage or hearing change can lead to investigation. These symptoms have many possible causes. Nasopharyngoscopy allows examination behind the nose and a directed biopsy; persistent symptoms deserve assessment even when the mouth looks normal.

Pathology distinguishes non-keratinizing carcinoma, keratinizing squamous carcinoma and rare basaloid carcinoma. Non-keratinizing tumors are commonly EBV-associated. EBER testing on tumor tissue helps establish that association; a positive blood antibody test alone does not diagnose cancer. A tumor in the nasopharynx can also be another disease, such as lymphoma.

MRI of the nasopharynx, skull base and neck maps local spread and nodes. PET/CT or other body imaging assesses distant disease according to risk. A routine brain scan is not a substitute for a dedicated nasopharyngeal study. Cranial-nerve symptoms, such as double vision or facial numbness, should be reported promptly.

AJCC Version 9 is the current nasopharyngeal staging system. Older reports and treatment trials may use earlier editions, so compare the actual T, N and M findings and the edition rather than assuming identical stage numbers mean identical disease. Neck-node involvement is regional spread; it does not by itself mean distant metastasis.

Plasma EBV DNA can help estimate risk and track response in EBV-associated cancer. Ask whether it was detectable before treatment, how it changed and whether the same laboratory method was used. Tissue EBER, blood EBV antibodies and plasma EBV DNA answer different questions.

A persistent or rising result may prompt repeat testing and examination or imaging. It is not, by itself, proof of a particular metastatic site or an automatic instruction to change drugs. An undetectable result likewise cannot exclude every residual or recurrent tumor.

Intensity-modulated radiotherapy (IMRT) is a mainstay of treatment. Selected lower-risk localized disease may receive radiation alone; higher-risk locoregional disease generally requires concurrent platinum-based chemotherapy when tolerable. Kidney function, hearing, nutrition and general fitness affect the choice of platinum and schedule.

For appropriate higher-risk patients, gemcitabine–cisplatin induction chemotherapy before concurrent chemoradiation improves disease control and survival compared with chemoradiation alone. Induction means treatment before radiation, not a replacement for it. Its added marrow and digestive toxicity must be balanced against the chance of completing the full curative plan.

Some regional pathways also include EGFR-directed nimotuzumab with radiation. China’s published product-indication record includes this combination for locally advanced nasopharyngeal cancer. Its use requires review of the local label and the proposed treatment backbone; it should not be treated as universally interchangeable with cisplatin or PD-1 therapy.

After definitive chemoradiation, selected high-risk patients may be offered adjuvant capecitabine. Randomized evidence, including longer follow-up, supports benefit in the studied population. This is not a requirement for every patient whose scan has cleared; recovery, recurrence risk, hand–foot symptoms and ability to tolerate further treatment matter.

PD-1 treatment is also moving into high-risk non-metastatic disease. DIPPER found improved event-free survival with adjuvant camrelizumab after induction and concurrent chemoradiation; CONTINUUM studied sintilimab across induction, concurrent and adjuvant phases. These are different strategies with different eligibility and toxicity. Ask which evidence matches your case and whether the proposed use is locally approved, guideline-supported or part of a trial.

Recurrence confined to the nasopharynx or neck is different from widespread metastatic disease. Restaging and, where feasible, tissue confirmation help distinguish recurrent cancer from radiation injury. Selected accessible recurrences may be treated by endoscopic nasopharyngectomy; neck-node recurrence may have a surgical option as well.

Reirradiation requires the original radiation plan, cumulative organ doses and a careful assessment of nearby vessels, nerves and brain tissue. Severe bleeding or tissue necrosis is a material risk. A proton or carbon-ion proposal should explain the patient-specific dose advantage and remaining risks; the technology name alone does not establish superiority.

When curative local treatment is not feasible, chemotherapy with a PD-1 inhibitor is an important first-line pathway. The precise product, chemotherapy partner and prior-treatment requirements vary by jurisdiction. The following examples describe current US indications; they do not imply identical access or approval elsewhere.

Neither of these NPC indications requires a positive PD-L1 result. Prior PD-1 exposure, autoimmune disease, transplant history and organ function still matter. Changing from one PD-1 drug to another after progression is not automatically an effective strategy.

Before treatment, arrange dental assessment, a hearing baseline and nutrition and swallowing support. During treatment, mouth soreness, taste change, dry mouth or nausea can make eating difficult. Report weight loss or dehydration early so support can be adjusted before treatment is disrupted.

Long-term review should address dry mouth, dental problems, reduced jaw opening, hearing loss, swallowing difficulty and thyroid or pituitary function. Tell any dentist about prior head-and-neck radiation before invasive treatment. With PD-1 therapy, new diarrhea, breathlessness, jaundice or marked fatigue can signal immune-related inflammation and needs prompt discussion with the care team.

Response is assessed with examination, endoscopy and appropriate imaging after time for early treatment effects to settle. Follow-up then considers symptoms, local findings, risk and EBV DNA where informative. A scan result should be read alongside its timing and prior images, rather than treating every persistent thickening as active cancer.

• Pathology with histological subtype and tissue EBV findings; the TNM findings and staging edition.
• Original MRI and body imaging, dated EBV DNA results with laboratory details, and a treatment timeline.
• Complete radiation planning files and dose summary if previously irradiated; current hearing, swallowing, dental and nutritional issues.